Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)
Vr. Dharnidharka et al., Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS), TRANSPLANT, 71(8), 2001, pp. 1065-1068
Background. Posttransplant lymphoproliferative disorder (PTLD) is an import
ant complication of transplantation, The North American Pediatric Renal Tra
nsplant Cooperative Study (NAPRTCS) database has documented 56 cases of PTL
D, the largest such series to date.
Methods, We analyzed the available longitudinal and multicenter data in the
NAPRTCS database to evaluate the demographic and therapeutic risk factors
and the temporal trends for PTLD in children after renal transplantation.
Results. The overall incidence of PTLD was 1.2% of all patients or 298/100,
000 posttransplantation years of follow-up, However, this incidence increas
ed from 254/100,000 years between 1987 and 1991 to 395/100,000 years from 1
992 onwards, In the same periods, the time to PTLD decreased from a median
of 356 days (range 64-3048) to a median of 190 days (range 42-944). PTLD oc
curred with greater frequency in white children (P=0,003) and in cadaver do
nor transplants (P=0,019), but there was no significant predilection for ge
nder, younger children (0-5 years), or primary diagnosis, No significant di
fference was found in the use of anti-T-cell antibodies or in doses of CsA,
azathioprine, or prednisone at 1 month, 6 months, and 1 year. Between 1996
and 1997, 69 patients were initiated with tacrolimus, Eight cases of PTLD
were identified in these recipients to date (prevalence rate 11.5%), compar
ed with 46/4084 (1.1%) where cyclosporine was used (P <0.0001),
Conclusions, There is a trend towards increasing incidence and earlier occu
rrence of PTLD in the pediatric renal transplant population. White race and
cadaver donor sources are risk factors not reported before. Continued moni
toring of tacrolimus immunosuppression is important.